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 Abstract 
 
Circular dichroism (CD) spectroscopic data indicate the conformational change of the triene 
moiety of the immunosuppressive agent sirolimus (rapamycin) upon its binding to human α1-
acid glycoprotein (orosomucoid). The development of an intense, negative π→π
*
 CD Cotton 
effect and the bathochromic shift of the corresponding UV band are attributed to the increased 
helical distortion of the conjugated π-system. Comparative chiroptical evaluation of the 
interaction of sirolimus with the separated genetic variants of orosomucoid indicates that the 
F1/S form is dominant in the amplification of the inherent chirality of the triene chromophore 
while the A variant induces much weaker structural modification. Consistently, the drug binding 
affinities of the native protein and the F1/S variant estimated from the CD spectra are close to 
each other (~2 × 10
5
 M
-1
). 
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α1-Acid glycoprotein (AAG), also named orosomucoid, is an abundant acute phase 
component of the human plasma, the exact biological function of which remains to be 
elucidated.
1, 2
 Its anti-inflammatory and immunosuppressive activity are well documented 
including the inhibition of neutrophil activation, lymphocyte proliferation, platelet 
aggregation and a variety of other immune functions.
3, 4
 As a member of the lipocalin family, 
the single polypeptide chain of AAG folds into a β-barrel structure enclosing a wide, central 
cavity where a broad array of organic compounds can be bound.
5, 6
 Macrolide antibiotics are 
typical AAG binding agents
7-9
 possessing a large macrocycle which is reminiscent to that of 
the potent immunosuppressive drug sirolimus (rapamycin). Sirolimus is a chiral, 
multichromophoric antifungal compound of bacterial origin consisting of triene, lactone, 
lactol, enone, and ketone moieties (Scheme 1).
10, 11
 The circular dichroism (CD) activity of 
the lactone and enone groups are displayed below 250 nm. The asymmetrically perturbed 
n→π
*
 transitions of the 9-, 26-, and 32-ones give rise to a negative CD band centered around 
300 nm (Fig. 1).
12
 The weak, π→π
*
 of origin contribution of the triene moiety is suppressed 
by the more intense carbonyl Cotton effects (CEs) and can only be seen as unresolved 
vibrational peaks on the short-wavelength side of the n→π
*
 feature.
12
 The presence of the 
AAG in the sample solution, however, deeply alters this chiroptical profile amplifying the CD 
amplitudes in the absorption region of the triene chromophore (Fig. 1). The molar dichroic 
absorption coefficient (∆ε) measured in protein-free buffer solution at 275 nm increases by 
ten-fold and the anisotropy factor (g = ∆ε/ε) between 260-280 nm raises also by an order of 
magnitude (~10
-4
 → ~10
-3
). Concomitantly, the gmax value of the n→π
*
 CE is 
bathochromically shifted by 5 nm (Fig. 2). The excitation energy of n→π
*
 transition of the 
carbonyl chromophore sensitively depends on the polarity of the medium.
13, 14
 The decrease of 
solvent polarity shifts it to longer wavelengths and vice versa. The blue shift exhibited in 
polar solvents is ascribed chiefly to hydrogen bonding between the >C=O group and the 
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solvent molecules with smaller contributions from a general dielectric effect. Therefore, the 
observed red shift is consistent with change of the highly polar and protic aqueous 
environment around some carbonyl groups of sirolimus to the less polar, hydrophobic binding 
site of AAG. 
Similarly to the allied UV peak, the induced π→π
*
 CE shows a characteristic vibrational 
progression. All of these changes attest that upon binding to AAG, the triene unit of sirolimus 
undergoes a significant conformational rearrangement. The overall helicity of the conjugated 
π-system strongly rises in AAG bound state that may occur by twisting around either C–C 
single or C=C double bonds with concomitant blue or red shift of the corresponding 
absorption band, respectively. The red shift observed in the present case (Fig. 1) suggests that 
the torsional deformation of the polyene chain required to fit the molecule to the protein 
binding site occurs by a rotation around the C=C double bonds.
15, 16
 Another possible source 
of the UV red shift of the triene moiety could be the replacement of the bulk aqueous phase 
by the apolar protein binding milieu. Decreasing of the solvent polarity, however, hardly 
affects the UV maxima of sirolimus (see inset in Fig. 1) suggesting that this effect is 
unimportant. Finally, the AAG binding induced helical distortion of the triene moiety is also 
supported by the less resolved vibrational peaks of the UV band of drug-protein complexes 
(Fig. 1) since  enhancement of the vibrational fine structure is associated with planarization of 
the polyene systems.
12
 
The binding of sirolimus to its the pharmacological target protein named FKBP is also 
accompanied with some modest CD and UV spectroscopic changes that refer to a more planar 
and rigid conformation of the triene moiety adopted at the binding site.
12
 
It is to be noted that the related immunosuppressive drug tacrolimus lacks the triene 
component. Despite of its AAG association,
17
 the intrinsic n→π
*
 CE of tacrolimus shows no 
alteration in protein solution (Fig. S1, ESI) pointing out the importance of the triene 
chromophore in the CD spectroscopic detection of the binding interaction. 
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Commercial AAG samples prepared from normal pooled serum consist of two main genetic 
variants called F1/S and A in a ratio of 70:30.
18, 19
 Due to sequence alterations (22 residues), 
the drug binding cavity of the variants differs from each other. 
6
 The wide, crevice-like pocket 
of the F1/S form is divided into three sub-chambers while the narrower cavity of the A variant 
consists only of two ones that accounts for their well documented distinct ligand binding 
properties.
20-22
 Therefore, the interaction of sirolimus with the separated genetic variants of 
AAG has also been studied. The F1/S variant induced very similar CD changes and UV shift 
as seen with the native sample (Fig. 3). In marked contrast, the A form caused a much smaller 
intensity gain of the π→π
*
 CE and only a minor red shift of the absorption maxima. 
Accordingly, F1/S binding plays a decisive contribution in the modification of the CD and 
UV spectroscopic profile of sirolimus. In relation to the A variant, entrapment of the drug 
molecule in the binding crevice of the F1/S form results in a significantly larger helical twist 
of the triene moiety. 
The CD curve of free sirolimus molecules displays a zero cross-over point around 270 nm but 
AAG binding produces non-zero, negative values in that region. Thus, the ellipticity data 
recorded at 270 nm during the titration of AAG solution with sirolimus can be used to 
estimate the binding affinity constant. Non-linear regression analysis yielded very similar Ka 
values (~2 × 10
5
 M
-1
) for the native protein as well as the F1/S variant (Fig. S2, ESI). The 
markedly smaller value than that of 1 obtained for n in the case of the native sample (the 
mixture of the genetic variants) might refer to the non-specific binding contribution of the A 
form. 
Overall, it is shown for the first time that the conformational chirality of the triene 
chromophore allows the chiroptical sensing and evaluation of sirolimus-AAG interactions 
providing a basis to use this methodology for studying related compounds, too (e.g., 
temsirolimus, everolimus, ridaforolimus). 
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Scheme 1  
Chemical structure of sirolimus (rapamycin).  
756x754mm (72 x 72 DPI)  
 
 
Page 12 of 21RSC Advances
  
 
 
Figure 1  
Difference CD and UV absorption spectra of sirolimus in the absence and in the presence of native AAG (pH 
7.4 Ringer buffer, 25 °C). Inset shows the absorption maxima of the drug measured in various solvents 
(THF, tetrahydrofuran; ACN, acetonitrile; EtOH, ethanol).  
663x878mm (72 x 72 DPI)  
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Figure 2  
The anisotropy factor (g value) of sirolimus (SRL) calculated in the absence and in the presence of the F1/S 
genetic variant of AAG.  
762x580mm (72 x 72 DPI)  
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Figure 3  
Comparison of the CD and UV spectroscopic changes of sirolimus induced by the F1/S and A genetic variants 
of AAG (pH 7.4 Ringer buffer, 25 °C).  
635x839mm (72 x 72 DPI)  
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Materials and methods 
 
Materials 
Native AAG (Sigma, cat# G9885, lot# 018K7535), sirolimus (LC Laboratories, cat# R-5000, 
lot# ASW-112), and tacrolimus (LC Laboratories, cat# F-4900, lot# ATH-109) were used as 
supplied. The F1/S and A genetic variants of AAG were separated following the method of 
Hervé  et  al.1 as described previously.2 The molar ratio of the F1/S:A genetic variants in the 
commercial native AAG mixture was 75:25. 
 
Preparation of drug and AAG solutions 
Stock solutions of sirolimus and tacrolimus were prepared freshly in HPLC grade ethanol. 
The volume of ethanol added into AAG solutions never exceeded 3% (v/v) and caused 
negligible effects on the protein CD spectrum. AAG was dissolved in physiological Ringer 
buffer, pH 7.4 (8.1 mM Na2HPO4·12H2O, 1.5 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, 0.8 
mM CaCl2, 1.1 mM MgCl2). AAG concentration was calculated for a molecular mass of 
40,000. 
Circular dichroism and UV absorption spectroscopic measurements 
CD and UV absorption spectra were recorded on a JASCO J-715 spectropolarimeter at 25 ± 
0.2 °C in a rectangular quartz cell of 1 cm optical path length (Hellma, USA). Temperature 
control was provided by a Peltier thermostat equipped with magnetic stirring. Each spectrum 
represents the average of three scans obtained by collecting data at a scan speed of 100 
nm/min. Absorption spectra were obtained by conversion of the high voltage (HT) values of 
the photomultiplier tube of the CD equipment into absorbance units. CD and UV curves of 
drug-AAG mixtures were corrected by blank protein solution. JASCO CD 
spectropolarimeters record data as ellipticity (‘’) in units of millidegrees (mdeg). The 
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quantity of ‘‘ is converted to ‘‘ values using the equation  = /(33982cl), where ‘‘ is 
the molar circular dichroic absorption coefficient expressed in M-1cm-1, ‘c’ is the molar 
concentration of the ligand (mol/L), and ‘l’ is the optical pathlength expressed in cm. 
Calculation of the AAG binding parameters of sirolimus 
The stoichiometry of sirolimus-AAG complexes was determined by linear regression analysis 
of the linear parts of the CD titration curves. Intersection of linear extrapolations of the first 
and plateau phase of the titration data provides the number of binding sites (n) per a protein 
molecule (Fig. S2, ESI). The obtained values were taken into account in calculation of the 
association constants. 
Drug-Protein binding can be quantified by the association constant (Ka): 
D + P ⇌ DP; 
 
  PD
DP
K a     (1) 
It is evident that  
[D] = cd - [DP]   (2)  
and 
[P] = cp - [DP]   (3) 
where cd and cp are the total molar concentrations of the drug and the protein, respectively. 
Since the formation of sirolimus-AAG complexes is responsible for the ICD signal measured 
at 270 nm, it can be written that 
ICD (mdeg) = k [DP]   (4) 
where k is a constant. Using equations 1-4, we obtain  
    







dpadpadp ccKccKcc
k
mICD 4
2
deg
211
 
Non-linear regression analysis of the ICD values using NLREG® (statistical  analysis 
program, ver. 3.4) was performed to obtain the value of Ka.  
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Supplementary Figure 1 
Comparison of CD spectra of tacrolimus measured in the absence and presence of native 
AAG (mixture of the genetic variants). Inset shows the chemical structure of the drug. 
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Supplementary Figure 2 
Non-linear regression analysis of the ellipticity changes of sirolimus obtained by titration of  
AAG solutions (solid lines are the results of curve fitting procedures). Association constants 
(Ka) estimated for the native protein and the F1/S genetic variant are shown. The number of 
the binding sites per a protein molecule (n) was estimated by linear regression analysis of the 
linear parts of the CD titration curves (red lines). 
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